Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The two largest individual shareholders in Cyxone AB, Ivar Nordqvist and Göran Ofsén, have announced that they are submitting a new proposal regarding the election and remuneration of Board members prior to the Annual General Meeting of Cyxone AB to be held on May 16, 2022. Due to this, the shareholders that submitted the original proposals presented in the notice announced that they are withdrawing their proposals.
The new proposal means that the board will consist of four board members, Bert Junno, Theresa Comiskey Olsen, Saad Gilani and Mikael Lindstam will be re-elected as board members and that Bert Junno will be re-elected as chairman of the board. Furthermore, the proposal means that board renumeration shall be paid in the amount of SEK 400,000 to the chairman of the board (SEK 450,000 in the previous year) and in the amount of SEK 200,000 to each of the other board members (SEK 225,000 in the previous year).
Disclaimer
This is a translation of the original Swedish version of the press release. In case of any discrepancy between this translation and the Swedish original, the latter shall prevail.
Contact
Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com
The information was submitted for publication, through the agency of the contact person set out above, at 16.55 a.m. CEST on 12th of May 2022.
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se.For more information, please visit www.cyxone.com